Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort

Blood. 2012 Jun 21;119(25):6172-3. doi: 10.1182/blood-2012-04-422204.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine / therapeutic use*
  • Cohort Studies
  • Compassionate Use Trials / methods
  • Compassionate Use Trials / statistics & numerical data
  • Female
  • Follow-Up Studies
  • France
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / etiology
  • Myelodysplastic Syndromes / mortality
  • Prognosis
  • Risk Factors
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Azacitidine